Pionyr and abcam extend partnership to evaluate trem2-expressing cells in cancer patients

South san francisco, calif. and cambridge, england, june 22, 2021 /prnewswire/ -- today pionyr immunotherapeutics, inc., a company developing first-in-class antibody therapeutics that increase the body's anti-tumor immunity and abcam (aim: abc) (nasdaq: abcm), a global innovator in life science reagents and tools, announced the extension of their collaboration with a new commercial licensing agreement to support the progression of py314, the first to the clinic of pionyr's compounds.
ABCM Ratings Summary
ABCM Quant Ranking